Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans
- PMID: 16003293
- DOI: 10.1016/j.clpt.2005.03.003
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans
Abstract
Background: Adenosine receptor stimulation induces several effects that could limit ischemia-reperfusion injury. We hypothesize that treatment with the nucleoside uptake inhibitor dipyridamole increases endogenous adenosine and limits ischemia-reperfusion injury in humans.
Methods: Ischemia-reperfusion injury was studied in forearm skeletal muscle by technetium Tc 99m-labeled annexin A5 scintigraphy. Ischemia-reperfusion injury was induced by unilateral forearm ischemic exercise. Immediately on reperfusion, annexin A5 labeled with technetium Tc 99m was administered intravenously, and ischemia-reperfusion injury was expressed as the percentage difference in radioactivity between the experimental arm and the control arm 1 and 4 hours after reperfusion. Targeting was quantified in the region of the thenar muscle and forearm flexor muscles. This approach was used in 9 healthy male volunteers after a 1-week treatment with dipyridamole (200 mg, slow release, twice daily) and in 23 control subjects.
Results: Dipyridamole treatment significantly reduced annexin A5 targeting in skeletal muscle compared with the control group (thenar region, 13% +/- 7% versus 22% +/- 15% at 1 hour after reperfusion and 9% +/- 6% versus 27% +/- 13% at 4 hours for dipyridamole and control groups, respectively [P = .01]; flexor region, 4% +/- 8% versus 7% +/- 6% at 1 hour after reperfusion and 1% +/- 4% versus 10% +/- 9% at 4 hours for dipyridamole and control groups, respectively [P = .01]).
Conclusions: One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle.
Similar articles
-
Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans.Circulation. 2005 Jan 18;111(2):173-8. doi: 10.1161/01.CIR.0000151612.02223.F2. Epub 2004 Dec 27. Circulation. 2005. PMID: 15623546
-
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):963-8. doi: 10.1161/ATVBAHA.108.179622. Epub 2009 Apr 9. Arterioscler Thromb Vasc Biol. 2009. PMID: 19359665 Clinical Trial.
-
Caffeine prevents protection in two human models of ischemic preconditioning.J Am Coll Cardiol. 2006 Aug 15;48(4):700-7. doi: 10.1016/j.jacc.2006.04.083. Epub 2006 Jul 24. J Am Coll Cardiol. 2006. PMID: 16904537 Clinical Trial.
-
Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury--a review.J Surg Res. 2008 Dec;150(2):304-30. doi: 10.1016/j.jss.2007.12.747. Epub 2008 Jan 22. J Surg Res. 2008. PMID: 19040966 Review.
-
Protection against ischemic-reperfusion injury of skeletal muscle: role of ischemic preconditioning and adenosine pretreatment.J Reconstr Microsurg. 1996 Aug;12(6):383-8. doi: 10.1055/s-2007-1006502. J Reconstr Microsurg. 1996. PMID: 8866378 Review.
Cited by
-
Invited Lectures : Overviews Purinergic signalling: past, present and future.Purinergic Signal. 2006 May;2(1):1-324. doi: 10.1007/s11302-006-9006-2. Epub 2006 May 15. Purinergic Signal. 2006. PMID: 18404494 Free PMC article. No abstract available.
-
Dipyridamole augments the antiinflammatory response during human endotoxemia.Crit Care. 2011;15(6):R289. doi: 10.1186/cc10576. Epub 2011 Nov 30. Crit Care. 2011. PMID: 22129171 Free PMC article. Clinical Trial.
-
Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury?J Cardiovasc Pharmacol. 2015 Jun;65(6):517-21. doi: 10.1097/FJC.0000000000000194. J Cardiovasc Pharmacol. 2015. PMID: 26070128 Free PMC article. Review.
-
The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers.Eur J Clin Pharmacol. 2016 Jun;72(6):725-30. doi: 10.1007/s00228-016-2039-8. Epub 2016 Mar 15. Eur J Clin Pharmacol. 2016. PMID: 26979520 Free PMC article. Clinical Trial.
-
Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V.Proc Am Thorac Soc. 2009 Aug 15;6(5):469-76. doi: 10.1513/pats.200901-001AW. Proc Am Thorac Soc. 2009. PMID: 19687221 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical